Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07173907Completed

Epi-on CuRV and Epi-off aCXL Protocols in the Management of Keratoconus

Role: lead

NCT07133737Enrolling By Invitation

5 Year Follow up of SMILE® Procedure for the Correction of Hyperopia

Role: lead

NCT05832749Unknown

Comparison of the Safety and Efficacy of Ophtesis Bio 3% With a Similar 3% Sodium Hyaluronate OVD

Role: lead

NCT04523558Not ApplicableCompleted

Evaluation of the Extended Depth of Focus After Bilateral Implantation of Hydrophobic IOLs

Role: lead

NCT03805425Not ApplicableUnknown

PiXL for Correction of Hyperopia

Role: lead

NCT03836898Not ApplicableCompleted

Presbyopic Phakic Intraocular Lens for Myopia Correction

Role: lead

All 6 trials loaded